Levi & Korsinsky notifies investors that it has commenced an investigation into Eli Lilly and Company (NYSE: LLY) concerning potential violations of the federal securities laws.
On May 1, 2025, Eli Lilly issued a press release reporting first quarter 2025 results and reaffirming guidance. In conjunction with this press release, Eli Lilly management commented on the decision made by CVS, one of the country’s largest pharmacies, to drop coverage for its popular weight-loss drug, Zepbound, in favor of competitor’s Wegovy. Notably, Eli Lilly’s CEO attributes 45% of the Company’s year-over-year revenue growth to strong sales of Zepbound and Mounjaro. Following this news, Eli Lilly’s stock price fell by $104.85 per share, or approximately 11.7% to close at $794.10 per share.
If you suffered a loss on your Eli Lilly securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





